2024
533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure
Bunick C, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Schuttelaar M, Irvine A, Levy G, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg J. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. British Journal Of Dermatology 2024, 190: ii35-ii36. DOI: 10.1093/bjd/ljad498.037.Peer-Reviewed Original ResearchNon-melanoma skin cancerMajor adverse cardiovascular eventsVenous thromboembolic eventsAtopic dermatitisAdverse eventsAdjudicated major adverse cardiovascular eventsOral Janus kinase 1Rate of serious infectionTreatment-emergent adverse eventsLong-term safety dataDuration of follow-upConcomitant topical corticosteroidsEfficacy of upadacitinibDouble-blind periodRate of adverse eventsPhase 3 studyDoses of upadacitinibEczematous skin lesionsExposure-adjusted ratesMATERIALS & METHODSYear of treatmentAdverse cardiovascular eventsBenefit-risk profileInflammatory skin diseaseLong-term safety
2022
JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies.
Daniele S, Bunick C. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies. Journal Of Drugs In Dermatology 2022, 21: 1298-1303. PMID: 36468956, DOI: 10.36849/jdd.7187.Peer-Reviewed Original ResearchConceptsIncidence of adverse eventsAdverse cardiac eventsNon-melanoma skin cancerSystemic therapyAdverse eventsAtopic dermatitisCardiac eventsJAK inhibitorsVenous thromboembolismControl patientsSkin cancerIncidence rateTreatment of atopic dermatitisSystemic immunosuppressive therapyRates of non-melanoma skin cancerTraditional systemic therapiesIncidence of malignancyLong-term clinical trial dataReference control populationAtopic dermatitis treatmentBaseline rateLow incidence rateClinical trial dataImmunosuppressive therapySystemic corticosteroids